Oral corticosteroids in poorly controlled asthma [1]

Journal of Allergy and Clinical Immunology

Volumn 115, Issue 1, 2005, Pages 200-201

  Colice, Gene L ^a   Stampone, Patti ^b   Leung, Donald Y M ^c   Szefler, Stanley J ^c  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b 3M COMPANY   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID DERIVATIVE; PREDNISOLONE;

AIRWAY OBSTRUCTION; ASTHMA; CALCULATION; GASTROESOPHAGEAL REFLUX; HUMAN; LETTER; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SLEEP DISORDER;

ADMINISTRATION, ORAL; ADULT; ASTHMA; CLINICAL TRIALS; FEMALE; HUMANS; HYDROXYCORTICOSTEROIDS; MALE; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 11344267280     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2004.07.065     Document Type: Letter

References (5)

1. National Asthma Education Program Expert panel II report: guidelines for the diagnosis and management of asthma 1997 US Department of Health and Human Services Bethesda (MD)
2. G. Gross, P.J. Thompson, P. Chervinsky, and J. Vanden Burgt and the Study Group. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 mcg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 mcg, for the treatment of moderate asthma Chest 115 1999 343 351
3. R.J. Davies, P. Stampone, and B.J. O'Connor Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose Respir Med 92 suppl 1998 23 31
4. S.J. Szefler, and D.Y.M. Leung Glucocorticoid-resistant asthma Eur Respir J 10 1997 1640 1647
5. M.T.S. Chan, D.Y.M. Leung, S.J. Szefler, and J.D. Spahn Difficult-to-control asthma J Allergy Clin Immunol 101 1998 594 601